R. Castro

发表

Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illness study for France, Germany, Italy, Spain and the UK

M. Stokes, Á. Benedict, A. Alcaraz, 2010, BJU international.

The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED—A Randomized, Placebo Controlled, Double‐Blind Clinical Trial

Brandon Whitcher, H. Ahmed, A. Freeman, 2017, The Journal of urology.

Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.

F. Schröder, A. Alcaraz, A. Tubaro, 2009, European urology.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

D. Tindall, D. Bostwick, T. Tammela, 2014, Urology.

The effect of dutasteride on MRI-defined prostate cancer lesions: MAPPED (Magnetic resonance imaging in Primary Prostate Cancer after Exposure to Dutasteride) - a randomized placebo-controlled, double-blind clinical trial

Brandon Whitcher, H. Ahmed, A. Freeman, 2017 .

Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study

F. Montorsi, F. Schröder, J. Wolff, 2009, BJU international.

Usefulness of prostate‐specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study

F. Montorsi, G. Andriole, S. Freedland, 2012, BJU international.

Reply from Authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice. Eur Urol 2013;63:788–9: 5-Alpha Reductase Inhibitors in Prostate Cancer

T. Tammela, F. Schröder, C. Bangma, 2013 .

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.

C. Roehrborn, G. Andriole, R. Rittmaster, 2011, European urology.

A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits

F. Montorsi, F. Schröder, A. Alcaraz, 2009, The Prostate.

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

D. Tindall, D. Bostwick, T. Tammela, 2011, The Journal of urology.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

T. Tammela, F. Schröder, C. Bangma, 2013, European urology.

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial

C. Roehrborn, G. Andriole, R. Rittmaster, 2011 .

Can simple tests performed in the primary care setting provide accurate and efficient diagnosis of benign prostatic hyperplasia? Rationale and design of the Diagnosis Improvement in Primary Care Trial

C. Cricelli, J. Carballido, A. Pagliarulo, 2009, International journal of clinical practice.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

C. Roehrborn, F. Montorsi, R. Castro, 2009, European urology.

159 PROSTATE CANCER RISK IN MEN WITH PROSTATE AND BREAST CANCER FAMILY HISTORY: RESULTS FROM THE REDUCE STUDY

Jianfeng Xu, G. Andriole, W. Isaacs, 2012 .

The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms.

B. Bemelmans, M. Busse, R. Castro, 2006, European urology.

Review - Neuro-Urology - Voiding Dysfunction The Placebo Effect in the Pharmacologic Treatment of Patients with Lower Urinary Tract Symptoms

M. Busse, R. Castro, J. H. S. Leeuwen, 2006 .

Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence: results from PURE.

B. Monz, S. Hunskaar, E. Chartier-Kastler, 2007, European urology.

Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries.

B. Monz, S. Hunskaar, G. Samsioe, 2005, Maturitas.

Tolerability of amine uptake inhibitors in urologic diseases.

H. Ruhé, M. Oelke, M. Michel, 2006, Current drug safety.

Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study

A. Bjartell, M. Somerville, L. Black, 2014, Prostate cancer.

MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial

Brandon Whitcher, F. Giganti, C. Moore, 2017, European Radiology.

Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial

A. Sessa, A. Boye, J. Carballido, 2011, International journal of clinical practice.

Nocturia improvement in the combination of Avodart® and tamsulosin (CombAT) study

C. Roehrborn, M. Manyak, M. Oelke, 2014, World Journal of Urology.

Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies

C. Roehrborn, M. Manyak, M. Oelke, 2014, World Journal of Urology.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

N. Fleshner, D. Margel, R. Castro, 2013, The Journal of urology.

The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.

G. Andriole, M. Manyak, R. Grubb, 2013, The Journal of urology.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

N. Fleshner, D. Margel, R. Castro, 2013, The Journal of urology.

The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.

G. Andriole, M. Manyak, R. Grubb, 2013, The Journal of urology.

C. Cricelli, J. Carballido, A. Pagliarulo, 2009, International journal of clinical practice.

960 THE INFLUENCE OF A POSITIVE FAMILY HISTORY ON PROSTATE CANCER INCIDENCE AND DUTASTERIDE EFFICACY IN THE REDUCE STUDY

T. Tammela, G. Andriole, R. Castro, 2010 .